A patient-funded ALS drug offers hope where few treatments exist

Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.

By Kelly Bilodeau • June 15, 2022

Woman of the Week: Tango Therapeutics' Dr. Barbara Weber

A pioneer in genetic medicine, Dr. Barbara Weber continues to push the envelope to expand the reach of therapies based on genetic targeting.

By Taren Grom • June 14, 2022

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Why biomanufacturing is the next innovation frontier for genomic therapies

While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.

By Meagan Parrish • June 13, 2022

Making moves: Civica, Astellas, Inozyme and more announce key new hires

The latest hiring moves from Civica, Astella, Inozyme and the Flagship Pioneering-founded Tessera Therapeutics. 

By Karissa Waddick • June 13, 2022

First 90 Days: Editas Medicine’s Gilmore O’Neill

The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

By Michael Gibney • June 13, 2022

A combo of precision meds and diagnostics could disrupt mental healthcare

HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.

By Kelly Bilodeau • June 8, 2022

First 90 Days: Janssen Immunology’s David Jimenez

The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

By Taren Grom • June 6, 2022

Flagship's creative approach to finding the next big idea in biopharma

Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.

By Alexandra Pecci • June 1, 2022

Cell and gene therapy advances coming fast and furious

A peek into R&D at the Mass General Brigham network reveals up-and-coming treatments pushing the boundaries of what’s possible in medicine.

By Kelly Bilodeau • June 1, 2022

Woman of the Week: OcuTerra Therapeutics' Kerrie Brady

The serial entrepreneur and now head of OcuTerra explains why taking risks in pharma pays off.

By Taren Grom • June 1, 2022

Making moves: Inovio, Veru, MindMed and more announce key new hires

The latest career moves in the biopharma industry from Veru, MindMed, Horizon Therapeutics and Inovio. 

By Karissa Waddick • May 25, 2022

The UK-based company that's striving to overcome the limitations of T cell receptor innovation

Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.

By Kim Ribbink • May 23, 2022

First 90 Days: Syneos Health’s Michelle Keefe

The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.

By Taren Grom • May 23, 2022

Tracking trends in healthcare, from tech to patient care

High-performing leaders honored by the Healthcare Businesswomen’s Association share their views on the future of the industry.

By Taren Grom • May 20, 2022

A potential COVID-19 EUA could turn this small biotech into a household name

Veru’s CEO discusses the impact of the upcoming FDA decision on its treatment targeting severely ill COVID-19 patients.

By Meagan Parrish • May 19, 2022

Woman of the Week: Sparrow Pharmaceuticals' Jamie MacPherson

The vice president of regulatory affairs and quality on embracing leadership challenges in drug development.

By Taren Grom • May 18, 2022

Jumping into pharma with big plans at a small company

SpringWorks Therapeutics' chief medical officer on the ambition that drives him and his company to develop treatments for cancer patients.

By Alexandra Pecci • May 17, 2022

Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

By Michael Gibney • May 17, 2022

Are digital DCTs the answer for rare diseases?

How data from EHRs is helping to identify, diagnose and recruit patients to decentralized clinical trials.

By Kim Ribbink • May 16, 2022

After 40 years, researchers discover new frontiers in the fight against HIV

Medical advances in the last two decades may now provide scientists with the right toolbox to target the long-elusive virus.

By Karissa Waddick • May 16, 2022

Why 'soft' skills matter in the new era of leadership

Standout leaders honored by the Healthcare Businesswomen's Association discuss the rising value of the interpersonal approach.

By Taren Grom • May 12, 2022

With the shine of amyloid fading, tau is a rising star in Alzheimer's

The tau theory in Alzheimer's is being put to the test with phase 3 trial results due later this month from TauRx Pharmaceuticals.

By Michael Gibney • May 11, 2022

In the hot pharma talent market, execs battle these recruitment misconceptions

One of the top recruiting firms in life sciences weighs in on how companies can attract the next wave of rising stars.

By Meagan Parrish • May 11, 2022

It's time to acknowledge access as a prescribing barrier

A new survey reveals how red tape limits patient access to doctor-preferred specialty drugs. 

By Karissa Waddick • May 11, 2022

FDA draft guidance may turn diversity in clinical trials from nice-to-have into a must-have

New guidance from the FDA will ‘up the ante’ for diversity considerations. Here’s how your company can prepare.

By Kelly Bilodeau • May 10, 2022